高盛首予阿尔克梅斯买入评级

华尔街洞察

2025/07/15

知名投行高盛最新发布研究报告，对爱尔兰生物制药公司阿尔克梅斯（ALKS）予以"买入"初始评级。该报告认为，阿尔克梅斯在神经系统疾病治疗领域的产品管线具有显著临床价值，其自主研发的抗抑郁药物LYBALVI®市场渗透率持续提升，叠加在研的阿尔茨海默症治疗项目取得突破性进展，公司盈利增长曲线有望超预期。

分析师特别指出，阿尔克梅斯独创的剂量精准控制技术平台已建立竞争壁垒，当前估值尚未充分反映其创新管线的商业化潜力。受此评级影响，阿尔克梅斯股价在美东时间7月15日盘前交易时段呈现放量上行态势。

（本文根据公开市场分析师评级信息综合整理）

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1104983830"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104983830\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1104983830?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-15 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104983830","market":"hk","top_or_hot":-1,"title":"高盛首予阿尔克梅斯买入评级","media":"华尔街洞察","content":"<p>知名投行高盛最新发布研究报告，对爱尔兰生物制药公司阿尔克梅斯（ALKS）予以\"买入\"初始评级。该报告认为，阿尔克梅斯在神经系统疾病治疗领域的产品管线具有显著临床价值，其自主研发的抗抑郁药物LYBALVI®市场渗透率持续提升，叠加在研的阿尔茨海默症治疗项目取得突破性进展，公司盈利增长曲线有望超预期。</p>\n<p>分析师特别指出，阿尔克梅斯独创的剂量精准控制技术平台已建立竞争壁垒，当前估值尚未充分反映其创新管线的商业化潜力。受此评级影响，阿尔克梅斯股价在美东时间7月15日盘前交易时段呈现放量上行态势。</p>\n<p>（本文根据公开市场分析师评级信息综合整理）</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛首予阿尔克梅斯买入评级</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛首予阿尔克梅斯买入评级\n</h2>\n\n<h4 class=\"meta\">\n\n2025-07-15 20:50 北京时间&nbsp;&nbsp;&nbsp;<strong>华尔街洞察</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>知名投行高盛最新发布研究报告，对爱尔兰生物制药公司阿尔克梅斯（ALKS）予以\"买入\"初始评级。该报告认为，阿尔克梅斯在神经系统疾病治疗领域的产品管线具有显著临床价值，其自主研发的抗抑郁药物LYBALVI®市场渗透率持续提升，叠加在研的阿尔茨海默症治疗项目取得突破性进展，公司盈利增长曲线有望超预期。\n分析师特别指出，阿尔克梅斯独创的剂量精准控制技术平台已建立竞争壁垒，当前估值尚未充分反映其创新管线的...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1104983830","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104983830","pubTimestamp":1752583830,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"知名投行高盛最新发布研究报告，对爱尔兰生物制药公司阿尔克梅斯（ALKS）予以\"买入\"初始评级。该报告认为，阿尔克梅斯在神经系统疾病治疗领域的产品管线具有显著临床价值，其自主研发的抗抑郁药物LYBALVI®市场渗透率持续提升，叠加在研的阿尔茨海默症治疗项目取得突破性进展，公司盈利增长曲线有望超预期。\n分析师特别指出，阿尔克梅斯独创的剂量精准控制技术平台已建立竞争壁垒，当前估值尚未充分反映其创新管线的商业化潜力。受此评级影响，阿尔克梅斯股价在美东时间7月15日盘前交易时段呈现放量上行态势。\n（本文根据公开市场分析师评级信息综合整理）","collect":0,"end_time":0,"defaultTopTitle":"laohu8.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","BK4550":"红杉资本持仓","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","BK4552":"Archegos爆仓风波概念","LU0251142724.SGD":"Fidelity America A-SGD","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","IE0004086264.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"A\" (USD) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE0004091025.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"B\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","BK4139":"生物科技","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","BK4127":"投资银行业与经纪业","LU0106831901.USD":"贝莱德世界金融基金A2","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","ALKS":"阿尔凯默斯","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","BK4516":"特朗普概念","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","BK4504":"桥水持仓","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC"},"translate_title":"Goldman Sachs Initiates Buy Rating on Alkmes","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALKS":1},"content_text":"知名投行高盛最新发布研究报告，对爱尔兰生物制药公司阿尔克梅斯（ALKS）予以\"买入\"初始评级。该报告认为，阿尔克梅斯在神经系统疾病治疗领域的产品管线具有显著临床价值，其自主研发的抗抑郁药物LYBALVI®市场渗透率持续提升，叠加在研的阿尔茨海默症治疗项目取得突破性进展，公司盈利增长曲线有望超预期。\n分析师特别指出，阿尔克梅斯独创的剂量精准控制技术平台已建立竞争壁垒，当前估值尚未充分反映其创新管线的商业化潜力。受此评级影响，阿尔克梅斯股价在美东时间7月15日盘前交易时段呈现放量上行态势。\n（本文根据公开市场分析师评级信息综合整理）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}